PharmaVOICE

Pharmaceutical companies invest more than$300 billion in research and development annually, but just12% of drugs entering clinical trials ultimately receive approval from the U.S. Food and Drug Administration (FDA). Even when therapies succeed, commercialization hinges on identifying eligible patients and the physicians treating them; it’s a challenge that has intensified as treatments become more targeted and inclusion criteria more complex. Diagnostic data is emerging as a strategic asset.

NEW YORK — Welo Life Sciences today launched as a dedicated brand within Welo Global, providing multilingual and content solutions to pharmaceutical, contract research, and medical device organizations operating in highly regulated global environments.

HOUSTON — HOUSTON (April 3, 2026) — BrYet US, Inc. (“BrYet”) — a biotechnology innovator focused on developing potentially curative therapies for advanced cancers — today announced that it will present a poster showcasing its lead oncology therapeutic, ML-016, at the American Association for Cancer Research (AACR) Annual Meeting 2026. The meeting will take place April 17-22, 2026, at the San Diego Convention Center in San Diego, California.

LAKE ZURICH, Ill. — As cancer incidence rises globally, including within the Sikh community, clinical research becomes increasingly essential for improving outcomes; yet participation among underrepresented populations remains low due to limited awareness and cultural or language barriers. Clinical trials provide access to innovative therapies, often unavailable outside research, along with closer monitoring and potentially more cost-effective care.

ATLANTA — Vector Global Logistics, an award-winning boutique logistics firm operating across multiple international locations, is recognizing B Corp Month while also commemorating its second year as a Certified B Corporation. As part of a global community of more than 10,000 companies that meet verified standards of social and environmental business practices, Vector is celebrating with B Corp-focused editions of its Logistics With Purpose® podcast.

ENGLEWOOD, N.J. — Xogene, a leader in clinical trial transparency solutions, announced the launch of Prime 4.0, the latest release of its end-to-end disclosure management platform. The release introduces significant changes to form architecture, data syncing, and overall system usability — designed to reduce manual effort and improve accuracy across multi-registry disclosure workflows.

COLUMBUS, Ohio — Columbus, OH and Sterling, VA – Tuesday 17th March: Gifthealth, the patient access solution that unifies the prescription journey from provider to patient, is deploying direct-to-patient (DTP) programs to deliver MFN pricing to consumers. Gifthealth is the nation’s largest DTP partner for manufacturers, dispensing more than 90% of current US DTP volume. Its digital-first model supports high-volume products with retail prices as low as $35.

When it comes to 340B, uncertainty has become an excuse. Decision-makers are fatigued: the rules are contested, headlines change weekly, and the safest move can feel like doing nothing. But waiting isn’t neutral—it lets others define your risk, margins, compliance posture, and ultimately how you manage your 340B exposure.

CAMBRIDGE, Mass. — TOKYO, Japan — PRISM BioLab Co., Ltd. (“PRISM”) and Receptor.AI Inc. today announced that they have entered into a drug discovery collaboration agreement (the “Collaboration”) to develop an integrated, AI-navigated, physics-guided platform targeting intracellular protein–protein interactions (PPIs) and complex receptor systems with orally available small molecules.

HOUSTON — HOUSTON (March 4, 2026) — BrYet US, Inc. (“BrYet”) — a biotechnology innovator focused on developing curative therapies for advanced cancers — announced today that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for its lead drug, ML-016. Upon approval, the IND will support the expansion of BrYet's ML-016 clinical program with additional trials in the United States.